Open AccessOverexpression of leucine‐rich α2‐glycoprotein‐1 is a prognostic marker and enhances tumor migration in gastric cancer
Author(s) -
Yamamoto Masaaki,
Takahashi Tsuyoshi,
Serada Satoshi,
Sugase Takahito,
Tanaka Koji,
Miyazaki Yasuhiro,
Makino Tomoki,
Kurokawa Yukinori,
Yamasaki Makoto,
Nakajima Kiyokazu,
Takiguchi Shuji,
Naka Testsuji,
Mori Masaki,
Doki Yuichiro
Publication year - 2017
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.13329
Subject(s) - cancer , medicine , immunohistochemistry , lymphovascular invasion , biomarker , stage (stratigraphy) , cancer cell , chemotherapy , oncology , pathology , metastasis , biology , paleontology , biochemistry
Gastric cancer is one of the most common malignant tumors. Although improvement in chemotherapy has been achieved, the clinical prognosis of advanced gastric cancer remains poor. Therefore, it is increasingly important to predict the prognosis and determine whether patients should or should not receive neoadjuvant or adjuvant chemotherapy. Leucine‐rich α2‐glycoprotein‐1 ( LRG 1) is overexpressed during inflammation and is associated with various malignancies. In this study, we assessed LRG 1 expression in cancer specimens and in the sera of patients with cancer to clarify the usefulness of LRG 1 as a biomarker in gastric cancer. This study enrolled 239 (for immunohistochemical staining; IHC ) and 184 (for ELISA ) patients with gastric cancer. Results of IHC showed that LRG 1 expression was significantly associated with histological type, lymphatic and venous invasion, tumor and node factors, and disease stage. Overall survival was significantly worse in the high LRG 1 expression group than in the low LRG 1 group ( P = 0.0003). Cox multivariate analysis of overall survival revealed that LRG 1 expression was an independent prognostic factor ( P = 0.0258). Serum LRG 1 was significantly higher in gastric cancer patients than in healthy volunteers, and increased as the pathological stage progressed. Furthermore, a significant correlation was revealed between serum LRG 1 level and LRG 1 expression with IHC ( P < 0.0001). Inhibition of LRG 1 significantly decreased cell proliferation in vitro (migratory and invasive capacity of gastric cancer cells). These results suggest that LRG 1 expression in tumors and serum may be a useful prognostic marker in gastric cancer patients.